27.01.2022 | COVID-19 | Letters of Biomedical and Clinical Research
Zur Zeit gratis
COVID-19 vaccination outcomes among patients with dermatomyositis: a multicentered analysis
verfasst von:
Haig Pakhchanian, Ahmad Saud, Rahul Raiker, Sinan Kardes, Rohit Aggarwal, Latika Gupta
Erschienen in:
Clinical Rheumatology
|
Ausgabe 7/2022
Einloggen, um Zugang zu erhalten
Excerpt
The BNT162b2, mRNA-1273, and Ad26.COV.2.S are the three vaccines that have been instrumental in managing the COVID-19 pandemic in the USA. Despite these vaccines being granted Emergency-Use Authorization by the FDA, safety and efficacy are unclear among autoimmune rheumatic disease patients as these populations were excluded from clinical trials [
1‐
3]. Speculations have been rife that vaccines may trigger autoimmunity, contributing to vaccine hesitancy among those with autoimmune rheumatic disorders such as dermatomyositis (DM) [
4]. Therefore, the goal was to evaluate the safety and effectiveness of COVID-19 vaccination among DM patients when compared to vaccinated controls using data from a federated database. …